Loading market dashboard
NovoCure Limited
NVCRHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.
Shares of NovoCure Limited (NASDAQ: NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Risk and Volatility NovoCure has a beta of
JPMorgan Chase and Co. lifted its stake in NovoCure Limited (NASDAQ: NVCR) by 104.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 282,184 shares of the medical equipment provider's stock after buying an additional 144,024 shares during the period. JPMorgan
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces.
The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported.
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
